ONCOLOGY NEWSFEED

The FDA granted accelerated approval to telisotuzumab vedotin-tllv a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression, as determined by an FDA-approved test, who have received a prior systemic therapy.

For more information, read the FDA announcement and the AbbVie Inc. press release.

The FDA recently approved belzutifan for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma.

For more information, read the FDA announcement and the Merck & Co., Inc. press release .

The FDA granted accelerated approval to the combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

For more information, read the FDA announcement and the Verastem press release .

FDA approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma and as a single agent for adults with metastatic non-keratinizing NPC.

For more information, read the FDA announcement .

The FDA approved nivolumab with ipilimumab for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.

For more information, read the FDA announcement or the Bristol Myers Squibb press release .

On April 10, the US Food and Drug Administration (FDA) approved larotrectinib, a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity.

For more information, read the Bayer press release .

On March 28, the US Food and Drug Administration (FDA) expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibitor therapy and are considered appropriate to delay taxane-based chemotherapy.

For more information, read the FDA announcement or the Novartis press release .

On April 8, the US Food and Drug Administration (FDA) approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer.

For more information, read the FDA announcement .

On March 28, the US Food and Drug Administration (FDA) approved durvalumab with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer.

For more information, read the FDA announcement .

On March 26, the US Food and Drug Administration (FDA) approved cabozantinib for the treatment of adult and pediatric patients aged 12 years or older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.

For more information, read the FDA announcement or the Exelixis press release .

On March 19, the US Food and Drug Administration (FDA) granted traditional approval to pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1.

For more information read the FDA announcement .

On March 11, the European Commission granted marketing authorization for imetelstat as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low, or intermediate-risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

For more information, read the Geron press release .

On March 4, the US Food and Drug Administration (FDA) approved tislelizumab-jsgr in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

For more information, read the Beigene press release .

On January 27, the US Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki for unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.

For more information, read the FDA announcement and the Daiichi Sankyo press release.

On February 14, the US Food and Drug Administration (FDA) approved vimseltinib, a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumors for which surgical resection will potentially cause worsening functional limitation or severe morbidity.

For more information, read the FDA announcement and the Deciphera press release .

On February 11, the US Food and Drug Administration (FDA) approved mirdametinib for adults and children aged 2 years and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that cannot be completely resected.

For more information, read the FDA announcement and the SpringWorks Therapeutics press release .

On February 11, the US Food and Drug Administration (FDA) approved brentuximab vedotin plus lenalidomide and rituximab for adults with relapsed or refractory large B-cell lymphoma who have undergone at least 2 lines of systemic therapy and are not candidates for autologous hematopoietic stem cell transplantation or CAR-T therapy.

For more information, read the FDA announcement and the Pfizer press release .

On January 21, the US Food and Drug Administration (FDA) approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome.

For more information, read the FDA Announcement or the Medexus press release.

Effective January 1, 2025, patients with Aetna® Medicare Advantage or SilverScript® coverage who have metastatic hormone-sensitive prostate cancer (mHSPC) and are new to NUBEQA® are subject to new prior authorization (PA) criteria. Some patients may be required to step through another medication before a PA for NUBEQA is approved. Patients with other Aetna plans, including commercial and Medicaid plans, other CVS Caremark® formularies, and plans through other insurance carriers are not affected. Additionally, mHSPC patients already on NUBEQA and patients with non-metastatic castration-resistant prostate cancer are not affected.

To learn more, visit Bayer Access Services .

On January 17, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

For more information, read the FDA announcement and the AstraZeneca press release .

Posted 1/28/2025

On January 24, the US Food and Drug Administration (FDA) released new information to increase awareness of recent updates to capecitabine and fluorouracil product labeling related to risks associated with dihydropyrimidine dehydrogenase deficiency.

For more information, read the FDA announcement .

On January 16, US the Food and Drug Administration (FDA) approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

For more information read the FDA announcement and the Amgen press release .

On January 16, the US Food and Drug Administration (FDA) granted traditional approval to acalabrutinib with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.

For more information read the FDA announcement and the AstraZeneca press release .

On December 20, the US Food and Drug Administration (FDA) approved encorafenib in combination with cetuximab and fluorouracil, leucovorin, and oxaliplatin for the treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.

For more information, read the Pfizer press release .